Indisulam: an anticancer sulfonamide in clinical development

Bibliography

• CASINI A, SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Sulfonamides and sulfonylated derivatives as anticancer agents. Curr. Cancer Drug Targets (2002) 2:55–75.
   PubMed Web of Science ®Google Scholar
• OWA T, NAGASU T: Novel sulphonamide derivatives for the treatment of cancer. Expert Opin. Ther. Patents (2000) 10:1725–1740.
   Web of Science ®Google Scholar
• ••Excellent and comprehensive review onanticancer sulfonamides.
   Google Scholar
• SUPURAN CT, BRIGANTI F, TILLI S, CHEGWIDDEN WR, SCOZZAFAVA A: Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents ? Bioorg. Med. Chem. (2001) 9:703–714.
   Web of Science ®Google Scholar
• OWA T, YOSHINO H, OKAUCHI T et al: Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. j Med. Chem. (1999) 42:3789–3799.
   PubMed Web of Science ®Google Scholar
• ••The original description of the synthesis and preliminary biological activity of indisulam.
   Google Scholar
• OWA T, OKAUCHI T, YOSHIMATSU K et al: A focused compound library of novel N-(7-indolyObenzenesulfonamides for the discovery of potent cell cycle inhibitors. Bioorg. Med. Chem. Lett. (2000) 10:1223–1226.
   PubMed Web of Science ®Google Scholar
• OWA T, YOSHINO H, OKAUCHI T et al: Synthesis and biological evaluation of N-(7-Indoly1)-3-pyridinesulfonamide derivatives as potent antitumor agents. Bioorg. Med. Chem. Lett. (2002) 12:2097–2100.
   PubMed Web of Science ®Google Scholar
• OWA T, YOKOI A, YAMAZAKI K, YOSHIMATSU K, YAMORI T, NAGASU T: Array-based structure and gene expression relationship study of antitumor sulfonamides including N- [2- [(4-Hydroxyphenyl)aminol-3-pyridinyll -4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyfi -1,4-benzenedisulfonamide. j Med. Chem. (2002) 45:4913–4922.
   PubMed Web of Science ®Google Scholar
• OZAWA Y, SUGI NH, NAGASU T et al.: E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur. j Cancer (2001) 37:2275–2282.
   PubMed Web of Science ®Google Scholar
• FUKUOKA K, USUDA J, IWAMOTO Y et al: Mechanism of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest. New Drugs (2001) 19:219–227.
   PubMed Web of Science ®Google Scholar
• YOKOI A, KUROMITSU J, KAWAI T etal.: Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis. Ma. Cancer Ther. (2002) 1:275–286.
   Google Scholar
• VAN KESTEREN C, MATHOT R, RAYMOND E etal.: Population pharmacokinetic analysis of the novel anti-cancer agent E7070 in a Phase I study using nonlinear mixed effect modelling (NONMEM). NCI EORTC Symp. New Drugs Cancer Ther. (2000) 11 (Abstract 340).
   Google Scholar
• VAN KESTEREN C, MATHOT R, RAYMOND E et al.: Population pharmacokinetics of the novel anticancer agent E7070 during four Phase I studies: Model building and validation. I OM. OricoL (2002) 19:4065–4073.
   Google Scholar
• VAN DEN BONGARD D H, PLUEM D, ROSING H et al.: Metabolism and excretion of E7070 after intravenous administration to cancer patients. Proc. Am. Soc. OM. arca (2001) 20 (Abstract 371).
   Google Scholar
• DITTRICH C, DUMEZ H, CAL VERT H et al.: Phase I and pharmacokinetic study of E7070 in patients with solid tumors as single iv infusion, weekly x 4, q 6 weeks. Proc. Am. Assoc. Cancer Res. (2000) 41 (Abstract 3875).
   Google Scholar
• DROZ JP, ROCHE H, ZANETTA S et al.: Phase I trial of five-days continuous infusion E7070 [N-(3-chloro-7-indoly1)-1,4-benzenedisulfonamidd in patients (pts) with solid tumors. Proc. Am. AMC. Cancer Res. (2000) 41 (Abstract 3876).
   Google Scholar
• PUNT CJA, FUMOLEAU P, WALLE BVD et al: Phase I and pharmacokinetic (PK) study of E7070, a novel sulphonamide, given daily x 5 every 3 weeks as a 1-hour intravenous infusion in patients (pts) with advanced solid tumors. Proc. Am. Assoc. Cancer Res. (2000) 41 (Abstract 3877).
   Google Scholar
• PUNT CJ, FUMOLEAU P, VAN DE WALLE B, FABER MN, RAVIC M, CAMPONE M: Phase I and pharmacokinetic study of E7070, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann. OricoL (2001) 12:1289–1293.
   Google Scholar
• VAN KESTEREN C, MATHOT RA, RAYMOND E et al: Population pharmacokinetics of the novel anticancer agent E7070 during four Phase I studies: Model building and validation. I OM. OricoL (2002) 20:4065–4073.
   PubMed Web of Science ®Google Scholar
• RAYMOND E, TEN BOKKEL HUINIK WW, TAIEB J etal.: Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor as an one hour infusion every three weeks in patients with advanced cancer. j OM. arca (2002) 20:3508–3521.
   Google Scholar
• MAINWARING PN, VAN CUTSEM E, VAN LAETHEM JL et al: A multicentre randomised Phase II study of E7070 in patients with colorectal cancer who have failed 5-fluorouracil-based chemotherapy. Proc. Am. Soc. OM. OricoL (2002) 21 (Abstract 611).
   Google Scholar
• TALBOT D, NORBURY C, SLADE M et al.: Phase II and pharmacodynamic study of E7070 in patients with Non-Small Cell Lung Cancer (NSCLC) who have failed platinum-based chemotherapy. Proc. Am. Soc. OM. Oncol. (2002) 21 (Abstract 1306).
   Google Scholar
• VAN KESTEREN C, BEIJNEN JH, SCHELLENS JH: E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. Anti-Cancer Drugs (2002) 13:989–997.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Patents (2000) 10:575–600.
   Web of Science ®Google Scholar
• ••Exhaustive review on carbonic anhydraseinhibitors and their applications in therapy.
   Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Applications of carbonic anhydrase inhibitors and activators in therapy. Expert Opin. Ther. Patents (2002) 12:217–242.
   Web of Science ®Google Scholar
• ••Update of the preceding reference, with thelast developments in the field, mainly in the design of anticancer carbonic anhydrase inhibitors.
   Google Scholar
• CHEGWIDDEN WR, SPENCER IM, SUPURAN CT: The roles of carbonic anhydrase isozymes in cancer. In: Gene Families: Studies of DNA, RNA, Enzymes and Proteins. G Xue, Y Xue, Z Xu, R Holmes, GL Hammond, HA Lim (Eds), World Scientific, Singapore (2001):157–170.
   Google Scholar